AI assistant
Cellectis — AGM Information 2015
May 20, 2015
1190_iss_2015-05-20_f9d58b0d-0f9b-4663-838f-44f4ea1b9965.pdf
AGM Information
Open in viewerOpens in your device viewer
PRESS RELEASE
Cellectis SA Combined General Shareholders' Meeting of May 18, 2015
Paris (France) – May 19, 2015 – The Combined General Shareholders' Meeting of Cellectis S.A. (Alternext: ALCLS – Nasdaq Global Market: CLLS) was held on Monday, May 18, 2015 in Paris, at the Group's headquarters.
At the end of the meeting, during which more than 75% of votes were exercised, all of the ten resolutions submitted for the shareholders' vote were approved.
In particular, Cellectis' shareholders voted on:
- the approval of the parent company and consolidated financial statements for the fiscal year ended December 31, 2014;
- term of office renewal of directors Mr André Choulika, Mr David Sourdive and Mr Alain Godard;
- the approval of regulated agreements;
- the authorization of a share repurchase plan and the authorization given to the Board of Directors to retire the shares acquired through it;
- the nomination of a new Director, Mr Jean-Marie Messier.
Jean-Marie Messier, 58 years old, is co-founder and head of Messier Maris & Associés, an investment bank headquartered in Paris and New-York. Messier Maris & Associés is recognized as a leading independent corporate finance advisor in mergers and acquisitions, financial restructuring and equity / debt advisory.
The full results of the vote can be examined on the company's website (www.cellectis.com).
About Cellectis
Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
For further information, please contact:
Media contact Jennifer Moore, Director of Communications Phone: 917-580-1088 email: [email protected]
BMC Communications Brad Miles Phone: 646-513-3125 email: [email protected]
IR contact
Simon Harnest, VP Finance and Investor Relations Phone: 646-385-9008 email: [email protected]